Endicott JA - Search Results

1

Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4.

Myers SM, Miller DC, Molyneux L, Arasta M, Bawn RH, Blackburn TJ, Cook SJ, Edwards N, Endicott JA, Golding BT, Griffin RJ, Hammonds T, Hardcastle IR, Harnor SJ, Heptinstall AB, Lochhead PA, Martin MP, Martin NC, Newell DR, Owen PJ, Pang LC, Reuillon T, Rigoreau LJM, Thomas HD, Tucker JA, Wang LZ, Wong AC, Noble MEM, Wedge SR, Cano C. Myers SM, et al. Among authors: endicott ja. Eur J Med Chem. 2019 Sep 15;178:530-543. doi: 10.1016/j.ejmech.2019.05.057. Epub 2019 May 25. Eur J Med Chem. 2019. PMID: 31212132

2

The cyclin box fold: protein recognition in cell-cycle and transcription control.

Noble ME, Endicott JA, Brown NR, Johnson LN. Noble ME, et al. Among authors: endicott ja. Trends Biochem Sci. 1997 Dec;22(12):482-7. doi: 10.1016/s0968-0004(97)01144-4. Trends Biochem Sci. 1997. PMID: 9433129 Review.

3

Structural principles in cell-cycle control: beyond the CDKs.

Endicott JA, Noble ME. Endicott JA, et al. Structure. 1998 May 15;6(5):535-41. doi: 10.1016/s0969-2126(98)00055-0. Structure. 1998. PMID: 9634691 Free article. Review.

4

Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies.

Noble ME, Endicott JA. Noble ME, et al. Among authors: endicott ja. Pharmacol Ther. 1999 May-Jun;82(2-3):269-78. doi: 10.1016/s0163-7258(98)00051-5. Pharmacol Ther. 1999. PMID: 10454204 Review.

5

The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases.

Brown NR, Noble ME, Endicott JA, Johnson LN. Brown NR, et al. Among authors: endicott ja. Nat Cell Biol. 1999 Nov;1(7):438-43. doi: 10.1038/15674. Nat Cell Biol. 1999. PMID: 10559988

6

Cyclin-dependent kinases: inhibition and substrate recognition.

Endicott JA, Noble ME, Tucker JA. Endicott JA, et al. Curr Opin Struct Biol. 1999 Dec;9(6):738-44. doi: 10.1016/s0959-440x(99)00038-x. Curr Opin Struct Biol. 1999. PMID: 10607671 Review.

7

Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex.

Legraverend M, Tunnah P, Noble M, Ducrot P, Ludwig O, Grierson DS, Leost M, Meijer L, Endicott J. Legraverend M, et al. J Med Chem. 2000 Apr 6;43(7):1282-92. doi: 10.1021/jm9911130. J Med Chem. 2000. PMID: 10753466

8

Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.

Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, Garman EF, Gibson AE, Golding BT, Grant S, Griffin RJ, Jewsbury P, Johnson LN, Lawrie AM, Newell DR, Noble ME, Sausville EA, Schultz R, Yu W. Arris CE, et al. Among authors: endicott ja. J Med Chem. 2000 Jul 27;43(15):2797-804. doi: 10.1021/jm990628o. J Med Chem. 2000. PMID: 10956187

9

Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives.

Gibson AE, Arris CE, Bentley J, Boyle FT, Curtin NJ, Davies TG, Endicott JA, Golding BT, Grant S, Griffin RJ, Jewsbury P, Johnson LN, Mesguiche V, Newell DR, Noble ME, Tucker JA, Whitfield HJ. Gibson AE, et al. Among authors: endicott ja. J Med Chem. 2002 Aug 1;45(16):3381-93. doi: 10.1021/jm020056z. J Med Chem. 2002. PMID: 12139449

10

Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2.

Johnson LN, De Moliner E, Brown NR, Song H, Barford D, Endicott JA, Noble ME. Johnson LN, et al. Among authors: endicott ja. Pharmacol Ther. 2002 Feb-Mar;93(2-3):113-24. doi: 10.1016/s0163-7258(02)00181-x. Pharmacol Ther. 2002. PMID: 12191604 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

102 results

Search Page